Valuation Update With 7 Day Price Move • Aug 04
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to €132, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 14x in the Professional Services industry in Europe. Total returns to shareholders of 45% over the past three years. New Risk • Aug 02
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: €3.7m This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks High level of debt (208% net debt to equity). Share price has been volatile over the past 3 months (12% average weekly change). Significant insider selling over the past 3 months (€3.7m sold). Recent Insider Transactions • Aug 02
President recently sold €3.5m worth of stock On the 29th of July, C. Hussey sold around 24k shares on-market at roughly €146 per share. This transaction amounted to 32% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was C.'s only on-market trade for the last 12 months. New Risk • Jul 30
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 22% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks High level of debt (208% net debt to equity). Share price has been volatile over the past 3 months (12% average weekly change). Large one-off items impacting financial results. Reported Earnings • Jul 29
Second quarter 2026 earnings released: EPS: US$1.93 (vs US$1.12 in 2Q 2025) Second quarter 2026 results: EPS: US$1.93 (up from US$1.12 in 2Q 2025). Revenue: US$475.0m (up 18% from 2Q 2025). Net income: US$31.2m (up 61% from 2Q 2025). Profit margin: 6.6% (up from 4.8% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.6% p.a. on average during the next 2 years, compared to a 5.5% growth forecast for the Professional Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. 공고 • Jul 28
Huron Consulting Group Elects of Dr. L. Thomas Richards as Director, Nominating and Corporate Governance Committee, Finance and Capital Allocation Committee and Technology and Information Security Committee, Effective July 23, 2026 Huron Consulting Group announced that Dr. L. Thomas Richards was elected to its Board of Directors, effective July 23, 2026, to serve until the 2027 Annual Meeting of Stockholders of Huron (the “2027 Annual Meeting”). Dr. Richards has been appointed to the Company’s Nominating and Corporate Governance Committee, Finance and Capital Allocation Committee and Technology and Information Security Committee, effective July 23, 2026. Dr. Richards is an experienced executive, senior advisor and board leader with deep expertise across life sciences and healthcare, capital markets, and corporate governance. Dr. Richards most recently served as Chair of the Board of Directors of WittKieffer, an executive search and leadership advisory firm serving the healthcare, higher education, and life sciences sectors. He previously served as Interim Chief Executive Officer of One Biomed, a molecular tools company, and Chief Executive Officer of TessArae, a molecular diagnostics company. He advises venture capital and private equity investors across the life sciences industry, with a focus on emerging technologies and innovation-driven growth and served as a Senior Advisor to Metis Genetics, One Biomed, and Nanomix. He also practiced academic medicine as an emergency physician and assistant professor at Stanford University and the University of California, San Francisco. Earlier in his career, Dr. Richards was an investment banker in the mergers and acquisitions (M&A) groups of Lazard Frères, UBS, and SG Cowen. Dr. Richards also has extensive governance experience serving on public, private, and nonprofit boards. He previously served on the board of directors of Cowen Group Inc., a publicly traded financial services firm, and has served as a director of TessArae and One Biomed. He also currently serves on the board of two non-profit organizations, The World Telehealth Initiative and the Surfrider Foundation. Dr. Richards received an M.D. from Harvard Medical School, an M.Phil. from the University of Sydney, and a B.A. from Yale University. He is a board-certified physician in Emergency Medicine. 
